Survodutide

BI 456906

Survodutide is a dual GLP-1/glucagon agonist from Boehringer Ingelheim. Where sema and tirz mainly hit appetite, survodutide's glucagon activation also goes after liver fat directly — reducing hepatic fat, improving metabolic function, and addressing fibrosis. Phase 3 just landed: 16.6% weight loss at 76 weeks. It's also in trials for MASH (fatty liver disease), which is the real differentiator. The GI side effects are standard GLP-1 class stuff but at higher rates: 75% of participants reported GI events versus 42% on placebo.

Protocol

Dose: Escalating: 0.3mg to 4.8mg weekly over ~17 weeks | Frequency: Once weekly subcutaneous injection | Cycle: Continuous — this is a pharmaceutical, not a cycle-on/off peptide | Route: SubQ

Reconstitution: Pre-filled pen in clinical trials. Research vials: follow concentration-specific instructions.. Use our free reconstitution calculator for exact syringe units.

Effects

• Weight loss (85%) — 16.6% body weight loss at 76 weeks in Phase 3 (~39 lbs average). Statistically significant versus placebo.
• Appetite suppression (80%) — GLP-1 agonism decreases appetite and increases satiety. Same mechanism as semaglutide.
• Hepatic fat reduction (65%) — The glucagon component directly reduces liver fat — this is what differentiates survodutide from pure GLP-1 drugs.
• Metabolic improvement (60%) — Improvements in metabolic markers including inflammation and fibrosis markers. The MASH data is what makes pharma analysts excited.

Side Effects

• Nausea (45%) — Hits hardest every time you bump the dose up. Subsides after a couple weeks at each level. The escalation schedule exists for a reason.
• Vomiting (20%) — Mostly during dose escalation phases. Temporary but not fun. Don't rush the titration.
• Diarrhea (25%) — Your gut motility is changing. Mild to moderate for most people. Hydrate.
• Constipation (15%) — Some people get the opposite GI effect. Bodies are unpredictable like that.

Evidence

Emerging evidence — Phase 3 SYNCHRONIZE-1 trial (April 2026) hit both co-primary endpoints: 16.6% body weight loss at 76 weeks versus 3.2% on placebo. That's roughly 39 lbs average. Phase 2 showed up to 19% weight loss at 46 weeks. Boehringer Ingelheim is pushing this hard as a dual GLP-1/glucagon agonist with liver benefits the pure GLP-1 drugs don't have.

Approval status: Phase 3 trials ongoing. Not yet approved.

References

1. le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol, 2024. PMID: 38330987
2. Sanyal AJ et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med, 2024. PMID: 38847460
3. Blüher M et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia, 2024. PMID: 38095657
4. Wharton S et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) Obesity (Silver Spring), 2025. PMID: 39495965
5. le Roux CW et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes Obes Metab, 2026. PMID: 41187967

Storage

• Lyophilized: Refrigerate 2-8C. Do not freeze. Keep in original packaging to protect from light.
• Reconstituted: Refrigerate at 2-8C. Use within 4 weeks. Pre-filled pens follow manufacturer storage guidance.
• Water: Clinical formulation is pre-mixed. Research vials use bacteriostatic water per manufacturer specs.
• Needle: Pre-filled pen uses built-in needle. Research SubQ: 30-31 gauge, 0.5 inch.

← Browse all peptides | Dose calculator →

These statements have not been evaluated by the FDA. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any protocol.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify